ArticleKidney international2025
Progress, challenges, and pragmatic concessions in predicting relative risk of kidney survival in ARPKD.
Article in Kidney international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00327860 (Chronic Kidney Disease in Children Prospective Cohort Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Autosomal recessive polycystic kidney disease is rare, with heterogeneous disease progression toward kidney failure. Risk stratification tools are needed to identify patients at higher risk of progression. Burgmaier et al. developed a relative risk score model in the international ARPKD registry for children older than 2 months of age without kidney failure. Their regression-based model included 5 predictors and yielded a simple prognostic score that classified "lower-risk" and "higher-risk" groups. Discrimination separating these 2 groups was good, but there are potential future opportunities for absolute risk prediction. We discuss considerations for the interpretation of relative risk scores and external validation of prediction models in rare diseases like autosomal recessive polycystic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.